Generic Cymbalta Approved
WEDNESDAY, Dec. 11, 2013 (HealthDay News) -- The first generic versions of the antidepressant drug Cymbalta (duloxetine delayed-release capsules) have been approved by the U.S. Food and Drug Administration.
License to produce generic Cymbalta was granted to Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Lupin Ltd., Sun Pharma Global FZE, Teva Pharmaceuticals USA, and Torrent Pharmaceuticals Ltd., the agency said Wednesday in a news release.
Duloxetine is prescribed to treat symptoms of depression, which may include: depressed mood, loss of interest in usual activities, changes in weight or appetite, sleep problems, feelings of guilt or worthlessness, inability to concentrate or suicidal thoughts, the FDA said.
Labeling on duloxetine and other antidepressants says these drugs could increase users' risks of suicidal thinking and behavior, particularly among children, teens and young adults. Users should be monitored closely for these warning signs, the agency advised.
Common side effects of duloxetine include nausea, dry mouth, drowsiness, loss of appetite, increased sweating and dizziness.
Generic drugs are equivalent in effect and strength to their brand-name counterparts, the FDA said.
The FDA has more about this approval.Related Articles
- First Newborn Screening Test Approved for Rare Immune Disorder
December 16, 2014
- FDA Warns Against Fetal 'Keepsake' Videos
December 16, 2014
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright ©2013 HealthDay. All rights reserved.